Compare DLB & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLB | ROIV |
|---|---|---|
| Founded | 1965 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 14.1B |
| IPO Year | 2005 | N/A |
| Metric | DLB | ROIV |
|---|---|---|
| Price | $67.61 | $21.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $93.60 | $21.94 |
| AVG Volume (30 Days) | 653.1K | ★ 6.5M |
| Earning Date | 01-28-2026 | 11-10-2025 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.62 | N/A |
| Revenue | ★ $1,349,130,000.00 | $20,329,000.00 |
| Revenue This Year | $5.03 | N/A |
| Revenue Next Year | $4.02 | $376.94 |
| P/E Ratio | $25.82 | ★ N/A |
| Revenue Growth | ★ 5.92 | N/A |
| 52 Week Low | $64.02 | $8.73 |
| 52 Week High | $89.66 | $22.45 |
| Indicator | DLB | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 68.21 |
| Support Level | $66.09 | $20.14 |
| Resistance Level | $68.84 | $21.48 |
| Average True Range (ATR) | 1.17 | 0.66 |
| MACD | 0.22 | -0.02 |
| Stochastic Oscillator | 52.04 | 87.12 |
Dolby Laboratories Inc. develops technologies that enhance audio and video capture, transmission, and playback, enabling high-quality experiences across movies, TV, music, sports, and more. The company designs and manufactures audio, imaging, accessibility, and related hardware and software mainly for cinema, including digital cinema servers and media encryption and packaging tools. It generates the majority of its revenue by licensing its technology, brand, and patents to device manufacturers and by selling cinema hardware and services. It operates as a single reportable segment, with revenue derived mainly from licensing and, to a lesser extent, from premium cinema technologies, across the United States and international markets.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.